Cantor Fitzgerald Reaffirms “Overweight” Rating for Trulieve Cannabis (NYSE:TRLV)

Trulieve Cannabis (NYSE:TRLV)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a report issued on Friday, Benzinga reports. They currently have a $15.00 target price on the stock. Cantor Fitzgerald‘s price objective indicates a potential upside of 37.70% from the stock’s previous close.

TRLV has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Trulieve Cannabis in a research report on Friday, September 11th. Wall Street Zen downgraded Trulieve Cannabis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $15.00.

Trulieve Cannabis Trading Down 1.0%

Shares of NYSE:TRLV opened at $10.89 on Friday. The business’s 50-day simple moving average is $11.15. The company has a quick ratio of 3.98, a current ratio of 5.94 and a debt-to-equity ratio of 0.45. The firm has a market cap of $2.10 billion and a P/E ratio of 99.03. Trulieve Cannabis has a 12-month low of $4.62 and a 12-month high of $13.28.

Trulieve Cannabis (NYSE:TRLV) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. The firm had revenue of $271.00 million during the quarter, compared to the consensus estimate of $268.82 million. Trulieve Cannabis had a negative return on equity of 4.24% and a negative net margin of 41.55%. As a group, equities research analysts predict that Trulieve Cannabis will post 0.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trulieve Cannabis

A number of hedge funds and other institutional investors have recently bought and sold shares of TRLV. PFS Partners LLC purchased a new position in Trulieve Cannabis during the 3rd quarter valued at about $33,000. Marion Wealth Management purchased a new position in Trulieve Cannabis during the 3rd quarter valued at about $109,000. Finally, Prime Capital Investment Advisors LLC purchased a new position in Trulieve Cannabis during the 3rd quarter valued at about $770,000.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes and sells medical and adult-use cannabis products. Its offerings include flower, pre-rolls, concentrates, vaporizers, edibles, tinctures, capsules and topical products, sold through retail dispensaries and other approved channels under brands such as Trulieve, Cultivar Collection, Muse, Roll One and Alchemy.

Founded in 2015, Trulieve initially built its business around Florida’s medical cannabis market and later expanded into additional U.S.